NCT02888743 · ADVERSE EVENTS

Adverse events

Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer · Source last updated 2026-07-31

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Adverse events occurred during the study; they are not necessarily caused by treatment. Serious events are not interchangeable with severe/grade 3–4 events. These safety populations may differ from efficacy populations.

Collection time frame: Two years
Other-event reporting threshold: 5%

SAEs and non-SAE adverse events reflect all degrees of relatedness to study intervention. Non-SAE events are adverse events that were new or worsening relative to baseline. A 5% threshold was used for reporting non-SAE events (NSCLC: 4 or more of 78, CRC: 1 or more).

Participants affected / participants at risk, as reported
Safety group	Serious events	Other events	Deaths
NSCLC Arm A (Tremelimumab, Durvalumab, HD-RT) Patients receive tremelimumab and durvalumab as in Arm C. Beginning at week 2, patients receive high dose radiation therapy QD over 10 days for up to 3 fractions. Durvalumab: Given IV Radiation Therapy: Undergo radiation therapy Tremelimumab: Given IV	9 / 26	25 / 26	15 / 26
NSCLC Arm B (Tremelimumab, Durvalumab, LD-RT) Patients receive tremelimumab and durvalumab as in Arm C. Beginning at week 2, patients receive low dose radiation therapy every 6 hours BID on weeks 2, 6, 10 and 14. Durvalumab: Given IV Radiation Therapy: Undergo radiation therapy Tremelimumab: Given IV	11 / 26	24 / 26	15 / 26
NSCLC Arm C (Tremelimumab, Durvalumab) Patients receive tremelimumab IV and durvalumab IV over 60 minutes every 4 weeks for up to 16 weeks in the absence of disease progression or unacceptable toxicity. Patients then receive durvalumab IV over 60 minutes 4 weeks after last combination dose for up to 9 additional doses. Durvalumab: Given IV Tremelimumab: Given IV	8 / 26	24 / 26	9 / 26
CRC Arm A (Tremelimumab, Durvalumab, HD-RT) Patients receive tremelimumab IV and durvalumab IV over 60 minutes every 4 weeks for up to 16 weeks in the absence of disease progression or unacceptable toxicity. Patients then receive durvalumab IV over 60 minutes 4 weeks after last combination dose for up to 9 additional doses. Beginning at week 2, patients receive high dose radiation therapy QD over 10 days for up to 3 fractions. Durvalumab: Given IV Radiation Therapy: Undergo radiation therapy Tremelimumab: Given IV	5 / 10	9 / 10	6 / 10
CRC Arm B (Tremelimumab, Durvalumab, LD-RT) Patients receive tremelimumab IV and durvalumab IV over 60 minutes every 4 weeks for up to 16 weeks in the absence of disease progression or unacceptable toxicity. Patients then receive durvalumab IV over 60 minutes 4 weeks after last combination dose for up to 9 additional doses. Beginning at week 2, patients receive low dose radiation therapy every 6 hours BID on weeks 2, 6, 10 and 14. Durvalumab: Given IV Radiation Therapy: Undergo radiation therapy Tremelimumab: Given IV	6 / 9	9 / 9	6 / 9

Group identifiers: EG000: NSCLC Arm A (Tremelimumab, Durvalumab, HD-RT) · EG001: NSCLC Arm B (Tremelimumab, Durvalumab, LD-RT) · EG002: NSCLC Arm C (Tremelimumab, Durvalumab) · EG003: CRC Arm A (Tremelimumab, Durvalumab, HD-RT) · EG004: CRC Arm B (Tremelimumab, Durvalumab, LD-RT)

Serious adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
1
num At Risk
26
num Events
2
group Id
EG001
num Affected
0
num At Risk
26
num Events
0
group Id
EG002
num Affected
1
num At Risk
26
num Events
1
group Id
EG003
num Affected
0
num At Risk
10
num Events
0
group Id
EG004
num Affected
0
num At Risk
9
num Events
0
term
Anemia
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Cardiac disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
0
num At Risk
26
num Events
0
group Id
EG001
num Affected
1
num At Risk
26
num Events
1
group Id
EG002
num Affected
0
num At Risk
26
num Events
0
group Id
EG003
num Affected
0
num At Risk
10
num Events
0
group Id
EG004
num Affected
0
num At Risk
9
num Events
0
term
Cardiac arrest
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Cardiac disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
0
num At Risk
26
num Events
0
group Id
EG001
num Affected
0
num At Risk
26
num Events
0
group Id
EG002
num Affected
1
num At Risk
26
num Events
1
group Id
EG003
num Affected
0
num At Risk
10
num Events
0
group Id
EG004
num Affected
0
num At Risk
9
num Events
0
term
Cyanosis
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Cardiac disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
1
num At Risk
26
num Events
1
group Id
EG001
num Affected
0
num At Risk
26
num Events
0
group Id
EG002
num Affected
0
num At Risk
26
num Events
0
group Id
EG003
num Affected
0
num At Risk
10
num Events
0
group Id
EG004
num Affected
0
num At Risk
9
num Events
0
term
Sinus Tachycardia
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Endocrine disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
0
num At Risk
26
num Events
0
group Id
EG001
num Affected
0
num At Risk
26
num Events
0
group Id
EG002
num Affected
0
num At Risk
26
num Events
0
group Id
EG003
num Affected
0
num At Risk
10
num Events
0
group Id
EG004
num Affected
1
num At Risk
9
num Events
1
term
Hypothyroidism
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Endocrine disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
1
num At Risk
26
num Events
1
group Id
EG001
num Affected
0
num At Risk
26
num Events
0
group Id
EG002
num Affected
0
num At Risk
26
num Events
0
group Id
EG003
num Affected
0
num At Risk
10
num Events
0
group Id
EG004
num Affected
0
num At Risk
9
num Events
0
term
Adrenal insufficiency
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Eye disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
0
num At Risk
26
num Events
0
group Id
EG001
num Affected
0
num At Risk
26
num Events
0
group Id
EG002
num Affected
0
num At Risk
26
num Events
0
group Id
EG003
num Affected
0
num At Risk
10
num Events
0
group Id
EG004
num Affected
1
num At Risk
9
num Events
1
term
Blurred vision
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
1
num At Risk
26
num Events
1
group Id
EG001
num Affected
1
num At Risk
26
num Events
1
group Id
EG002
num Affected
1
num At Risk
26
num Events
1
group Id
EG003
num Affected
0
num At Risk
10
num Events
0
group Id
EG004
num Affected
1
num At Risk
9
num Events
1
term
Abdominal pain
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
0
num At Risk
26
num Events
0
group Id
EG001
num Affected
0
num At Risk
26
num Events
0
group Id
EG002
num Affected
0
num At Risk
26
num Events
0
group Id
EG003
num Affected
1
num At Risk
10
num Events
3
group Id
EG004
num Affected
2
num At Risk
9
num Events
4
term
Ascites
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
1
num At Risk
26
num Events
1
group Id
EG001
num Affected
0
num At Risk
26
num Events
0
group Id
EG002
num Affected
0
num At Risk
26
num Events
0
group Id
EG003
num Affected
0
num At Risk
10
num Events
0
group Id
EG004
num Affected
0
num At Risk
9
num Events
0
term
Colitis
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
0
num At Risk
26
num Events
0
group Id
EG001
num Affected
0
num At Risk
26
num Events
0
group Id
EG002
num Affected
1
num At Risk
26
num Events
1
group Id
EG003
num Affected
0
num At Risk
10
num Events
0
group Id
EG004
num Affected
0
num At Risk
9
num Events
0
term
Constipation
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
1
num At Risk
26
num Events
1
group Id
EG001
num Affected
1
num At Risk
26
num Events
1
group Id
EG002
num Affected
1
num At Risk
26
num Events
1
group Id
EG003
num Affected
1
num At Risk
10
num Events
1
group Id
EG004
num Affected
0
num At Risk
9
num Events
0
term
Diarrhea

Other reported adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
0
num At Risk
26
num Events
0
group Id
EG001
num Affected
0
num At Risk
26
num Events
0
group Id
EG002
num Affected
0
num At Risk
26
num Events
0
group Id
EG003
num Affected
0
num At Risk
10
num Events
0
group Id
EG004
num Affected
1
num At Risk
9
num Events
1
term
Absolute Neutrophil Count
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
4
num At Risk
26
num Events
6
group Id
EG001
num Affected
7
num At Risk
26
num Events
13
group Id
EG002
num Affected
4
num At Risk
26
num Events
7
group Id
EG003
num Affected
4
num At Risk
10
num Events
5
group Id
EG004
num Affected
6
num At Risk
9
num Events
15
term
Anemia
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
0
num At Risk
26
num Events
0
group Id
EG001
num Affected
0
num At Risk
26
num Events
0
group Id
EG002
num Affected
0
num At Risk
26
num Events
0
group Id
EG003
num Affected
1
num At Risk
10
num Events
1
group Id
EG004
num Affected
3
num At Risk
9
num Events
6
term
Decreased Hematocrit
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
0
num At Risk
26
num Events
0
group Id
EG001
num Affected
0
num At Risk
26
num Events
0
group Id
EG002
num Affected
0
num At Risk
26
num Events
0
group Id
EG003
num Affected
1
num At Risk
10
num Events
3
group Id
EG004
num Affected
2
num At Risk
9
num Events
3
term
Decreased MCHC
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
0
num At Risk
26
num Events
0
group Id
EG001
num Affected
0
num At Risk
26
num Events
0
group Id
EG002
num Affected
0
num At Risk
26
num Events
0
group Id
EG003
num Affected
1
num At Risk
10
num Events
1
group Id
EG004
num Affected
1
num At Risk
9
num Events
2
term
Decreased RBC
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
0
num At Risk
26
num Events
0
group Id
EG001
num Affected
0
num At Risk
26
num Events
0
group Id
EG002
num Affected
0
num At Risk
26
num Events
0
group Id
EG003
num Affected
1
num At Risk
10
num Events
1
group Id
EG004
num Affected
0
num At Risk
9
num Events
0
term
Elevated Absolute Monocyte
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
0
num At Risk
26
num Events
0
group Id
EG001
num Affected
0
num At Risk
26
num Events
0
group Id
EG002
num Affected
0
num At Risk
26
num Events
0
group Id
EG003
num Affected
1
num At Risk
10
num Events
2
group Id
EG004
num Affected
0
num At Risk
9
num Events
0
term
Elevated Bands
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
0
num At Risk
26
num Events
0
group Id
EG001
num Affected
0
num At Risk
26
num Events
0
group Id
EG002
num Affected
0
num At Risk
26
num Events
0
group Id
EG003
num Affected
1
num At Risk
10
num Events
1
group Id
EG004
num Affected
0
num At Risk
9
num Events
0
term
Elevated BUN
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
0
num At Risk
26
num Events
0
group Id
EG001
num Affected
0
num At Risk
26
num Events
0
group Id
EG002
num Affected
0
num At Risk
26
num Events
0
group Id
EG003
num Affected
0
num At Risk
10
num Events
0
group Id
EG004
num Affected
1
num At Risk
9
num Events
1
term
Eosinophil Count Elevated
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
0
num At Risk
26
num Events
0
group Id
EG001
num Affected
0
num At Risk
26
num Events
0
group Id
EG002
num Affected
0
num At Risk
26
num Events
0
group Id
EG003
num Affected
0
num At Risk
10
num Events
0
group Id
EG004
num Affected
1
num At Risk
9
num Events
1
term
Increased Monocyte Count
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
0
num At Risk
26
num Events
0
group Id
EG001
num Affected
0
num At Risk
26
num Events
0
group Id
EG002
num Affected
0
num At Risk
26
num Events
0
group Id
EG003
num Affected
2
num At Risk
10
num Events
3
group Id
EG004
num Affected
0
num At Risk
9
num Events
0
term
Increased Neutrophils
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
0
num At Risk
26
num Events
0
group Id
EG001
num Affected
0
num At Risk
26
num Events
0
group Id
EG002
num Affected
0
num At Risk
26
num Events
0
group Id
EG003
num Affected
0
num At Risk
10
num Events
0
group Id
EG004
num Affected
1
num At Risk
9
num Events
1
term
Increased Platelets

Complete source fields

description

event Groups

deaths Num Affected
15
deaths Num At Risk
26
description
Patients receive tremelimumab and durvalumab as in Arm C. Beginning at week 2, patients receive high dose radiation therapy QD over 10 days for up to 3 fractions. Durvalumab: Given IV Radiation Therapy: Undergo radiation therapy Tremelimumab: Given IV
id
EG000
other Num Affected
25
other Num At Risk
26
serious Num Affected
9
serious Num At Risk
26
title
NSCLC Arm A (Tremelimumab, Durvalumab, HD-RT)
deaths Num Affected
15
deaths Num At Risk
26
description
Patients receive tremelimumab and durvalumab as in Arm C. Beginning at week 2, patients receive low dose radiation therapy every 6 hours BID on weeks 2, 6, 10 and 14. Durvalumab: Given IV Radiation Therapy: Undergo radiation therapy Tremelimumab: Given IV
id
EG001
other Num Affected
24
other Num At Risk
26
serious Num Affected
11
serious Num At Risk
26
title
NSCLC Arm B (Tremelimumab, Durvalumab, LD-RT)
deaths Num Affected
9
deaths Num At Risk
26
description
Patients receive tremelimumab IV and durvalumab IV over 60 minutes every 4 weeks for up to 16 weeks in the absence of disease progression or unacceptable toxicity. Patients then receive durvalumab IV over 60 minutes 4 weeks after last combination dose for up to 9 additional doses. Durvalumab: Given IV Tremelimumab: Given IV
id
EG002
other Num Affected
24
other Num At Risk
26
serious Num Affected
8
serious Num At Risk
26
title
NSCLC Arm C (Tremelimumab, Durvalumab)
deaths Num Affected
6
deaths Num At Risk
10
description
Patients receive tremelimumab IV and durvalumab IV over 60 minutes every 4 weeks for up to 16 weeks in the absence of disease progression or unacceptable toxicity. Patients then receive durvalumab IV over 60 minutes 4 weeks after last combination dose for up to 9 additional doses. Beginning at week 2, patients receive high dose radiation therapy QD over 10 days for up to 3 fractions. Durvalumab: Given IV Radiation Therapy: Undergo radiation therapy Tremelimumab: Given IV
id
EG003
other Num Affected
9
other Num At Risk
10
serious Num Affected
5
serious Num At Risk
10
title
CRC Arm A (Tremelimumab, Durvalumab, HD-RT)
deaths Num Affected
6
deaths Num At Risk
9
description
Patients receive tremelimumab IV and durvalumab IV over 60 minutes every 4 weeks for up to 16 weeks in the absence of disease progression or unacceptable toxicity. Patients then receive durvalumab IV over 60 minutes 4 weeks after last combination dose for up to 9 additional doses. Beginning at week 2, patients receive low dose radiation therapy every 6 hours BID on weeks 2, 6, 10 and 14. Durvalumab: Given IV Radiation Therapy: Undergo radiation therapy Tremelimumab: Given IV
id
EG004
other Num Affected
9
other Num At Risk
9
serious Num Affected
6
serious Num At Risk
9
title
CRC Arm B (Tremelimumab, Durvalumab, LD-RT)

frequency Threshold

other Events

assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
0
num At Risk
26
num Events
0
group Id
EG001
num Affected
0
num At Risk
26
num Events
0
group Id
EG002
num Affected
0
num At Risk
26
num Events
0
group Id
EG003
num Affected
0
num At Risk
10
num Events
0
group Id
EG004
num Affected
1
num At Risk
9
num Events
1
term
Absolute Neutrophil Count
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
4
num At Risk
26
num Events
6
group Id
EG001
num Affected
7
num At Risk
26
num Events
13
group Id
EG002
num Affected
4
num At Risk
26
num Events
7
group Id
EG003
num Affected
4
num At Risk
10
num Events
5
group Id
EG004
num Affected
6
num At Risk
9
num Events
15
term
Anemia
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
0
num At Risk
26
num Events
0
group Id
EG001
num Affected
0
num At Risk
26
num Events
0
group Id
EG002
num Affected
0
num At Risk
26
num Events
0
group Id
EG003
num Affected
1
num At Risk
10
num Events
1
group Id
EG004
num Affected
3
num At Risk
9
num Events
6
term
Decreased Hematocrit
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
0
num At Risk
26
num Events
0
group Id
EG001
num Affected
0
num At Risk
26
num Events
0
group Id
EG002
num Affected
0
num At Risk
26
num Events
0
group Id
EG003
num Affected
1
num At Risk
10
num Events
3
group Id
EG004
num Affected
2
num At Risk
9
num Events
3
term
Decreased MCHC
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
0
num At Risk
26
num Events
0
group Id
EG001
num Affected
0
num At Risk
26
num Events
0
group Id
EG002
num Affected
0
num At Risk
26
num Events
0
group Id
EG003
num Affected
1
num At Risk
10
num Events
1
group Id
EG004
num Affected
1
num At Risk
9
num Events
2
term
Decreased RBC
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
0
num At Risk
26
num Events
0
group Id
EG001
num Affected
0
num At Risk
26
num Events
0
group Id
EG002
num Affected
0
num At Risk
26
num Events
0
group Id
EG003
num Affected
1
num At Risk
10
num Events
1
group Id
EG004
num Affected
0
num At Risk
9
num Events
0
term
Elevated Absolute Monocyte
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
0
num At Risk
26
num Events
0
group Id
EG001
num Affected
0
num At Risk
26
num Events
0
group Id
EG002
num Affected
0
num At Risk
26
num Events
0
group Id
EG003
num Affected
1
num At Risk
10
num Events
2
group Id
EG004
num Affected
0
num At Risk
9
num Events
0
term
Elevated Bands
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
0
num At Risk
26
num Events
0
group Id
EG001
num Affected
0
num At Risk
26
num Events
0
group Id
EG002
num Affected
0
num At Risk
26
num Events
0
group Id
EG003
num Affected
1
num At Risk
10
num Events
1
group Id
EG004
num Affected
0
num At Risk
9
num Events
0
term
Elevated BUN
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
0
num At Risk
26
num Events
0
group Id
EG001
num Affected
0
num At Risk
26
num Events
0
group Id
EG002
num Affected
0
num At Risk
26
num Events
0
group Id
EG003
num Affected
0
num At Risk
10
num Events
0
group Id
EG004
num Affected
1
num At Risk
9
num Events
1
term
Eosinophil Count Elevated
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
0
num At Risk
26
num Events
0
group Id
EG001
num Affected
0
num At Risk
26
num Events
0
group Id
EG002
num Affected
0
num At Risk
26
num Events
0
group Id
EG003
num Affected
0
num At Risk
10
num Events
0
group Id
EG004
num Affected
1
num At Risk
9
num Events
1
term
Increased Monocyte Count
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
0
num At Risk
26
num Events
0
group Id
EG001
num Affected
0
num At Risk
26
num Events
0
group Id
EG002
num Affected
0
num At Risk
26
num Events
0
group Id
EG003
num Affected
2
num At Risk
10
num Events
3
group Id
EG004
num Affected
0
num At Risk
9
num Events
0
term
Increased Neutrophils
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
0
num At Risk
26
num Events
0
group Id
EG001
num Affected
0
num At Risk
26
num Events
0
group Id
EG002
num Affected
0
num At Risk
26
num Events
0
group Id
EG003
num Affected
0
num At Risk
10
num Events
0
group Id
EG004
num Affected
1
num At Risk
9
num Events
1
term
Increased Platelets

serious Events

assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
1
num At Risk
26
num Events
2
group Id
EG001
num Affected
0
num At Risk
26
num Events
0
group Id
EG002
num Affected
1
num At Risk
26
num Events
1
group Id
EG003
num Affected
0
num At Risk
10
num Events
0
group Id
EG004
num Affected
0
num At Risk
9
num Events
0
term
Anemia
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Cardiac disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
0
num At Risk
26
num Events
0
group Id
EG001
num Affected
1
num At Risk
26
num Events
1
group Id
EG002
num Affected
0
num At Risk
26
num Events
0
group Id
EG003
num Affected
0
num At Risk
10
num Events
0
group Id
EG004
num Affected
0
num At Risk
9
num Events
0
term
Cardiac arrest
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Cardiac disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
0
num At Risk
26
num Events
0
group Id
EG001
num Affected
0
num At Risk
26
num Events
0
group Id
EG002
num Affected
1
num At Risk
26
num Events
1
group Id
EG003
num Affected
0
num At Risk
10
num Events
0
group Id
EG004
num Affected
0
num At Risk
9
num Events
0
term
Cyanosis
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Cardiac disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
1
num At Risk
26
num Events
1
group Id
EG001
num Affected
0
num At Risk
26
num Events
0
group Id
EG002
num Affected
0
num At Risk
26
num Events
0
group Id
EG003
num Affected
0
num At Risk
10
num Events
0
group Id
EG004
num Affected
0
num At Risk
9
num Events
0
term
Sinus Tachycardia
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Endocrine disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
0
num At Risk
26
num Events
0
group Id
EG001
num Affected
0
num At Risk
26
num Events
0
group Id
EG002
num Affected
0
num At Risk
26
num Events
0
group Id
EG003
num Affected
0
num At Risk
10
num Events
0
group Id
EG004
num Affected
1
num At Risk
9
num Events
1
term
Hypothyroidism
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Endocrine disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
1
num At Risk
26
num Events
1
group Id
EG001
num Affected
0
num At Risk
26
num Events
0
group Id
EG002
num Affected
0
num At Risk
26
num Events
0
group Id
EG003
num Affected
0
num At Risk
10
num Events
0
group Id
EG004
num Affected
0
num At Risk
9
num Events
0
term
Adrenal insufficiency
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Eye disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
0
num At Risk
26
num Events
0
group Id
EG001
num Affected
0
num At Risk
26
num Events
0
group Id
EG002
num Affected
0
num At Risk
26
num Events
0
group Id
EG003
num Affected
0
num At Risk
10
num Events
0
group Id
EG004
num Affected
1
num At Risk
9
num Events
1
term
Blurred vision
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
1
num At Risk
26
num Events
1
group Id
EG001
num Affected
1
num At Risk
26
num Events
1
group Id
EG002
num Affected
1
num At Risk
26
num Events
1
group Id
EG003
num Affected
0
num At Risk
10
num Events
0
group Id
EG004
num Affected
1
num At Risk
9
num Events
1
term
Abdominal pain
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
0
num At Risk
26
num Events
0
group Id
EG001
num Affected
0
num At Risk
26
num Events
0
group Id
EG002
num Affected
0
num At Risk
26
num Events
0
group Id
EG003
num Affected
1
num At Risk
10
num Events
3
group Id
EG004
num Affected
2
num At Risk
9
num Events
4
term
Ascites
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
1
num At Risk
26
num Events
1
group Id
EG001
num Affected
0
num At Risk
26
num Events
0
group Id
EG002
num Affected
0
num At Risk
26
num Events
0
group Id
EG003
num Affected
0
num At Risk
10
num Events
0
group Id
EG004
num Affected
0
num At Risk
9
num Events
0
term
Colitis
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
0
num At Risk
26
num Events
0
group Id
EG001
num Affected
0
num At Risk
26
num Events
0
group Id
EG002
num Affected
1
num At Risk
26
num Events
1
group Id
EG003
num Affected
0
num At Risk
10
num Events
0
group Id
EG004
num Affected
0
num At Risk
9
num Events
0
term
Constipation
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
1
num At Risk
26
num Events
1
group Id
EG001
num Affected
1
num At Risk
26
num Events
1
group Id
EG002
num Affected
1
num At Risk
26
num Events
1
group Id
EG003
num Affected
1
num At Risk
10
num Events
1
group Id
EG004
num Affected
0
num At Risk
9
num Events
0
term
Diarrhea

time Frame

Two years

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice